The Motley Fool
18 Oct 2026, 01:00 UTC · 2h ago
Impact · against what's priced in
The news for Beam Therapeutics is marginally positive but lacks a major catalyst. While Cathie Wood's continued accumulation shows institutional confidence, the $2.8 million purchase is negligible relative to her existing $220.4 million position.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
Beam Therapeutics holds $1.15 billion in cash as of the second quarter, providing a runway through mid-2029.
Priced inanalysis of Q2 results reported earlier
So whatWith only $32.2M in H1 revenue, the company relies entirely on this buffer to avoid dilution until at least FY2029.
More positive than 88% of claims this week
Cathie Wood's Ark Genomic Revolution fund spent $2.8 million on Beam shares on October 12 and 13.
Continue reading
5 related stories
Cathie Wood's recent $2.8 million purchase signals continued conviction, though it is a small addition to a total position of $220.4 million. The company's $1.15 billion cash runway through 2029 provides a critical safety buffer against dilution.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Newtrades occurred Oct 12-13, published Oct 18
So whatThis addition represents a small fraction of Wood's total $220.4 million position in the name.
More positive than 69% of claims this week
Beam filed a lawsuit against Serapha Bio and YolTech Therapeutics for the alleged theft of trade secrets regarding an AATD treatment.
Priced inno timing evidence provided in text
More positive than 57% of claims this week
Beam reported a $2.09 loss per share for the first six months of the year, compared to a $2.12 loss in the prior year period.
Priced inanalysis of H1 results reported earlier
So whatThe marginal improvement of $0.03 per share suggests a stagnant burn rate despite the 50.5% revenue growth.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
The article recommends it as a worthwhile buy due to its advanced base editing technology, strong cash runway, and pipeline.
More positive than 53% of ticker scores this week
Mentioned as a major pharmaceutical collaborator supporting Beam's balance sheet.
More positive than 53% of ticker scores this week
Mentioned as a major pharmaceutical collaborator supporting Beam's balance sheet.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
8h ago
More positive than 30% of relationship scores this week
[mutual] Beam has a pharmaceutical collaboration partnership with Pfizer.
—
BEAM hasn't traded since this ran. Last close $23.47 (Oct 16); the reaction starts at the next open.
BEAM chart →
